Kevin has more than 25 years of industry and academia experience in immunology. His work has largely focused on understanding lymphocyte activation and discovering and developing therapeutics to modulate lymphocyte activity. Prior to Seismic, Kevin helped start Pandion Therapeutics as the second employee, where he led the Immunology and Biomarker groups. Kevin built a successful interdisciplinary discovery team at Pandion, which was acquired by Merck in 2021 for $1.85 billion, to discover and develop a pipeline of biologics-based therapies to treat autoimmunity. Prior to Pandion, Kevin was a key member of the Immunology Pharmacology group at Abbvie where, among other responsibilities, he led the biology efforts to discover a small molecule GPCR agonist with colon-restricted activity to treat IBD. Before Abbvie, Kevin led the biology efforts at Biogen to discover and develop small molecule inhibitors of BTK to treat multiple autoimmune diseases and a biologics program targeting long-lived plasma cells. Kevin is a member of the scientific advisory board of Eurofins Scientific. Kevin graduated magna cum laude from Washington University in St. Louis with a bachelor’s degree in Molecular Biology and Biochemistry. He holds a Ph.D. in Immunology from the University of Washington in Seattle. Kevin did his post-doctoral training in Klaus Rajewsky’s lab at Harvard University.